EUVIMEDEUVIMED entdecken
Crossref

The Challenges of Precision Oncology Drug Development and Implementation

Simon J Hollingsworth, Andrew V Biankin

Public Health Genomics · 2015 · 18 (6) · 338-348

DOI: 10.1159/000441557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Public Health Genomics, online erschienen am 11.11.2015. Verfasst von Simon J Hollingsworth und 1 weiteren Autor:innen. Beteiligte Einrichtung: AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Drug Discovery. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Wellcome Trust, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The drivers of precision medicine are clear: for patients (and physicians) - more options, durable clinical benefit, reduced exposure to non-effective drugs and potential to leverage current scientific and technological advances; for the pharmaceutical industry - the potential to tackle core challenges in discovering and developing better and more efficacious medicines, to reduce rates of attrition in drug development and to reduce development costs; for healthcare systems and payers - improved efficiency through the provision of effective care and avoiding ineffective treatments. Oncology has been at the vanguard, the improvements gained in patient survival notable. However, the increasing number of molecular subgroups requires an equally increasing number (and new generation) of highly selective agents targeting inevitably lower incidence molecular segments. Innovative trial designs (umbrella/basket studies) are emerging as a patient-centric approach to drug development, and the rise in public-private partnerships, cross-industry, government and non-profit sector collaborations is enabling implementation of complex clinical trial designs. This poses significant challenges for healthcare systems and regulatory approval. Further substantial evolution of policy and processes, particularly regulatory requirements for approval for new therapeutics, are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DiscoveryClinical Trials as TopicCooperative BehaviorDrug ApprovalDrug IndustryHumansMedical OncologyMolecular Targeted TherapyPatient SelectionPrecision MedicinePublic-Private Sector Partnerships

Autor:innen und Institutionen

  • AstraZeneca, Cambridge, UK.

Förderung

  • Wellcome Trust
  • Cancer Research UK

Zitieren

APA

Hollingsworth, S. J., & Biankin, A. V. (2015). The Challenges of Precision Oncology Drug Development and Implementation. Public Health Genomics, 18(6), 338-348. https://doi.org/10.1159/000441557

Vancouver

Hollingsworth SJ, Biankin AV. The Challenges of Precision Oncology Drug Development and Implementation. Public Health Genomics. 2015;18(6):338-348. doi:10.1159/000441557

BibTeX
@article{Hollingsworth2015,
  author = {Hollingsworth, Simon J and Biankin, Andrew V},
  title = {The Challenges of Precision Oncology Drug Development and Implementation},
  journal = {Public Health Genomics},
  year = {2015},
  volume = {18},
  number = {6},
  pages = {338--348},
  doi = {10.1159/000441557}
}
Kostenlos starten →